PRNewswire

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world’s first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ — Dizal

ISTANBUL, Nov. 8, 2024 /PRNewswire/ — ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, has hosted its annual 5G Summit & User Congress 2024 in Istanbul, Türkiye. The two-day event, organized under the theme

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: